Background: Some patients with COVID-19 develop life-threatening thrombotic complications including myocardial infarction, deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, and ischemic stroke. These inflammatory and hypercoagulable states have been well documented in patient cohorts from metropolitan areas, but not in more rural populations, nor has a data-driven treatment plan been developed for thrombotic COVID-19 patients.
Methods: We undertook a retrospective case-control study of COVID-19-positive patients to analyze the impact of thrombosis on various clinical endpoints including terminal diagnosis and disease severity.
The diagnosis and treatment of low back pain must be standardized, based on evidence and solid research. The cost to individuals and society is great and only those diagnostic tests or treatments that can improve the quality and cost of care should be advocated.
View Article and Find Full Text PDF